Radiologic response of chemotherapy alone versus radiation and chemotherapy in the treatment of locally-advanced or advanced thymic epithelial tumors.
Induction therapy
radiation therapy
thoracic surgery
thymic carcinoma
thymoma
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
06
2020
revised:
05
08
2020
accepted:
06
08
2020
pubmed:
2
9
2020
medline:
13
8
2021
entrez:
2
9
2020
Statut:
ppublish
Résumé
Here, we investigated radiological responses following chemotherapy alone as compared to both radiation/chemotherapy (chemoRT) in patients with thymic epithelial tumors (TETs) who did not receive upfront surgery. TETs treated at a tertiary academic cancer center between January 2007 and July 2018 were identified. Patients received chemotherapy or chemoRT as initial therapy and pre- and post-treatment scans were available. Student's t-test, Wilcoxon rank-sum tests, and Cox proportional hazards method were used to compare clinical details and survival between groups. The primary outcome was change in tumor size, which was compared between groups using linear mixed-effects regression models, adjusting for baseline tumor size, age, and histology. A total of 24 of 114 patients with TETs identified met the inclusion criteria. The majority of patients had 67% thymoma (67%, n = 16) and AJCC8 III-IVA disease (58%, n = 14). Median age was 58.5 years (range: 33-76), median initial tumor volume was 187.1 cc (range: 28.7-653.6) and diameter was 8.5 cm (range: 4.5-14.3). Half of the patients received upfront chemotherapy (n = 12: 83% cisplatin/adriamycin/cyclophosphamide) or chemoRT (n = 12: 58% carboplatin/paclitaxel; median RT dose: 63 Gy [range: 60-70 Gy]). At a median imaging follow-up of 15 months (range: 0-86): ChemoRT was associated with increased average radiological response compared to chemotherapy alone (volume: -47.0 cc more, P < 0.001; diameter: -0.8 cm more, P = 0.03). In eight patients who received chemotherapy, 33% saw further tumor shrinkage (median volume: -42.3%, P = 0.03; diameter: -3.0%, P = 0.049) with additional radiation/chemoradiation. Median survival increased for patients ultimately receiving surgery versus those who did not (46 month, range: 16-127 vs. 14 month, range: 6-82; P < 0.01). ChemoRT produced a greater radiologic response compared to chemotherapy alone in patients with TETs not suitable for upfront resection. SIGNIFICANT FINDINGS OF THE STUDY: We found that chemoRT was associated with a greater radiologic response compared to patients who received chemotherapy alone. What this study adds: In patients with TET not amenable to upfront resection, chemoRT may be a feasible strategy for cytoreduction.
Sections du résumé
BACKGROUND
Here, we investigated radiological responses following chemotherapy alone as compared to both radiation/chemotherapy (chemoRT) in patients with thymic epithelial tumors (TETs) who did not receive upfront surgery.
METHODS
TETs treated at a tertiary academic cancer center between January 2007 and July 2018 were identified. Patients received chemotherapy or chemoRT as initial therapy and pre- and post-treatment scans were available. Student's t-test, Wilcoxon rank-sum tests, and Cox proportional hazards method were used to compare clinical details and survival between groups. The primary outcome was change in tumor size, which was compared between groups using linear mixed-effects regression models, adjusting for baseline tumor size, age, and histology.
RESULTS
A total of 24 of 114 patients with TETs identified met the inclusion criteria. The majority of patients had 67% thymoma (67%, n = 16) and AJCC8 III-IVA disease (58%, n = 14). Median age was 58.5 years (range: 33-76), median initial tumor volume was 187.1 cc (range: 28.7-653.6) and diameter was 8.5 cm (range: 4.5-14.3). Half of the patients received upfront chemotherapy (n = 12: 83% cisplatin/adriamycin/cyclophosphamide) or chemoRT (n = 12: 58% carboplatin/paclitaxel; median RT dose: 63 Gy [range: 60-70 Gy]). At a median imaging follow-up of 15 months (range: 0-86): ChemoRT was associated with increased average radiological response compared to chemotherapy alone (volume: -47.0 cc more, P < 0.001; diameter: -0.8 cm more, P = 0.03). In eight patients who received chemotherapy, 33% saw further tumor shrinkage (median volume: -42.3%, P = 0.03; diameter: -3.0%, P = 0.049) with additional radiation/chemoradiation. Median survival increased for patients ultimately receiving surgery versus those who did not (46 month, range: 16-127 vs. 14 month, range: 6-82; P < 0.01).
CONCLUSIONS
ChemoRT produced a greater radiologic response compared to chemotherapy alone in patients with TETs not suitable for upfront resection.
KEY POINTS
SIGNIFICANT FINDINGS OF THE STUDY: We found that chemoRT was associated with a greater radiologic response compared to patients who received chemotherapy alone.
WHAT THIS STUDY ADDS
What this study adds: In patients with TET not amenable to upfront resection, chemoRT may be a feasible strategy for cytoreduction.
Identifiants
pubmed: 32869525
doi: 10.1111/1759-7714.13635
pmc: PMC7529575
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2924-2931Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Lung Cancer. 2004 Jun;44(3):369-79
pubmed: 15140551
J Surg Oncol. 1996 Sep;63(1):17-22
pubmed: 8841462
J Thorac Oncol. 2011 Jul;6(7):1267-73
pubmed: 21610525
Transl Oncol. 2012 Feb;5(1):19-25
pubmed: 22348172
Cancer. 1991 Aug 15;68(4):706-13
pubmed: 1855170
Br J Cancer. 2010 Jun 29;103(1):6-11
pubmed: 20551960
Lung Cancer. 2014 May;84(2):175-81
pubmed: 24646831
Ann Thorac Surg. 2008 Feb;85(2):385-9
pubmed: 18222230
Educ Psychol Meas. 2016 Feb;76(1):64-87
pubmed: 29795857
Ann Thorac Surg. 2004 May;77(5):1860-9
pubmed: 15111216
Eur J Cancer. 2008 Jan;44(1):123-30
pubmed: 18068351
Ann Thorac Surg. 2016 Aug;102(2):e139-41
pubmed: 27449450
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Thorac Cardiovasc Surg. 2014 Jan;147(1):36-44, 46.e1
pubmed: 24139613
Chang Gung Med J. 2004 Jul;27(7):515-22
pubmed: 15508874
Ann Oncol. 1993 May;4(5):429-31
pubmed: 8353078
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S119-24
pubmed: 25396308
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S323-6
pubmed: 20859127
J Natl Compr Canc Netw. 2013 May 1;11(5):562-76
pubmed: 23667206